>>Signaling Pathways>> Others>>WNK-IN-11

WNK-IN-11

Catalog No.GC30175

WNK-IN-11은 WNK1에 대해 IC50이 4nM인 알로스테릭 WNK(With-No-Lysine) 키나제 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

WNK-IN-11 Chemical Structure

Cas No.: 2123489-30-3

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$211.00
재고 있음
5mg
US$207.00
재고 있음
10mg
US$342.00
재고 있음
25mg
US$602.00
재고 있음
50mg
US$855.00
재고 있음
100mg
US$1,215.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

WNK-IN-11 is an allosteric With-No-Lysine (WNK) kinase inhibitor, with an IC50 of 4 nM for WNK1.

WNK-IN-11 (compound 11) shows IC50<2 μM in the cellular OSR1 phosphorylation assay with reasonable aqueous solubility, albeit with still rather high microsomal clearance. WNK-IN-11 shows ATP noncompetitive inhibition. When tested against a panel of 440 human kinases at 10 μM concentration, 2500-fold above enzyme IC50 value, WNK-IN-11 shows excellent selectivity with only a few significant off-target kinase inhibitions, most notably BTK and feline encephalitis virus-related (FER) kinase, neither of which are implicated for blood pressure regulation. This excellent selectivity profile is consistent with the predicted allosteric binding mode outside the highly conserved ATP-pocket[1].

[1]. Yamada K, et al. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models. J Med Chem. 2017 Aug 24;60(16):7099-7107.

리뷰

Review for WNK-IN-11

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WNK-IN-11

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.